People channel feed – Endpoints News

People channel feed

Good salary, nice bonus — but why did biotech mogul David Hung gamble on Axovant?

9 years ago

The master dealmaker is back: David Hung takes the helm at Vivek Ramaswamy's Axovant

9 years ago

With a competitive Bill Sibold taking the helm at Sanofi Genzyme, longtime exec David Meeker makes an exit

9 years ago

Why wait? Trump mounts an early raid on NIH’s ’17 budget in search of some spending money

9 years ago

A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0

9 years ago

Ex-Baxalta CEO Ludwig Hantson gets the top job at a troubled Alexion

9 years ago

Novartis research leader takes the helm at Forty Seven, a CIRM-backed fledgling already deep in the clinic

9 years ago

Eli Lilly unveils an $850M makeover as Trump pounds the table for new US jobs, manufacturing

9 years ago

After selling a failed Cerulean for scrap value, the executive team wins a bonus reward

9 years ago

After a rough year in the trenches, Alnylam CEO John Maraganore and his team take a big cut in compensation

9 years ago

Trump’s budget takes a big bite out of the NIH, with big new fees for biopharma

9 years ago

Biopharma execs give Scott Gottlieb’s nomination for FDA commish (almost) a standing O in Endpoints poll

9 years ago

Pfizer vet Germano makes quick exit from Intrexon as hands-on billionaire Kirk reorganizes biotech

9 years ago

Under the gun after Opdivo setbacks, Bristol-Myers Squibb names a new chief scientist

9 years ago

High-profile biotech leader Deborah Dunsire takes the helm at XTuit, focused on cancer and fibrosis

9 years ago

Icahn hires on gene therapy legend—and big biotech disruptor—Richard Mulligan as Bristol-Myers rumors simmer

9 years ago

Jackie Fouse is “retiring” from the president’s job at Celgene. Really?

9 years ago

PhRMA disses Marathon CEO—and PhRMA board member—Jeff Aronin after latest price gouging controversy

9 years ago

The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump

9 years ago

Celgene co-founder Sol Barer bags a Johns Hopkins immuno-oncology spinout in buyout

9 years ago

A swarm of top biotech execs protest against Trump’s travel ban, saying it threatens the entire industry

9 years ago

As crisis deepens, Teva's board sees off CEO Erez Vigodman and an activist urges a split into two companies

9 years ago

Another top Genentech exec gets poached, this time taking the helm at CAR-T player Bellicum

9 years ago

Francis Collins gets a reprieve, held over as NIH chief under Trump — for now

9 years ago

First page Previous page 96 97 9899100 101 Next page Last page